Purple Biotech LTD.: Form 20-F for the period ended Dec 31, 2024
Filed with the SEC on Mar 10, 2025 and accepted by EDGAR at Mar 10, 2025, 16:06 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Net income | 12 months2024-01-01 to 2024-12-31 | −$7.2m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | $4.99 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | $4.44 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −$14.4m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2024-12-31 | $7.4m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2024-12-31 | $8.9m | ifrs-full:CurrentAssets |
| Total assets | At period end2024-12-31 | $37.0m | ifrs-full:Assets |
| Current liabilities | At period end2024-12-31 | $4.0m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | At period end2024-12-31 | $32.9m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2024-12-31 | 517,128,717 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-25-022192. Last ingested by Listed: Nov 6, 2026, 18:16 ET. Listed shows no prices and gives no investment advice.